← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 150개
CGTBiologicstalePaolo Caimi, MDPhase 1

Allogeneic NK cells (Allogeneic NK cells)

Non Hodgkin Lymphoma; B-cell Non Hodgkin Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#인기#세포유전치료+4
효능 ORR 5%임상시험 58상태 RECRUITING
CGTBiologicstaleNovartis PharmaceuticalsPhase 2

Bridging Therapy (Bridging Therapy)

Non-Hodgkin Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#CGT#Phase2#인기#세포유전치료+4
효능 ORR 32.1%임상시험 58상태 DISCONTINUED
ADCBiologicstaleSeagenvedotin-containing regimen …Phase 2

BV (BrentuximabVedotin, BrentuximabVedotin (BV))

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 2%임상시험 56상태 ACTIVE
CGTBiologicstaleHebei Senlang Biotechnology Inc…Preclinical

CD19+CD22 CAR-T (CD19+CD22 CAR-T)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#인기#세포유전치료+5
임상시험 53상태 ACTIVE
CGTBiologicstaleCRISPR Therapeutics AGPhase 2

CD19-directed CAR-T cells (CD19-directed CAR-T cells)

B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 25%임상시험 53상태 ACTIVE
CGTBiologicstaleMatthew FrankPhase 1

CD22 CAR (CD22 CAR)

B-ALL; B-cell Non Hodgkin Lymphoma · CD22

#CD22#CGT#Phase1#인기#세포유전치료+5
임상시험 53상태 ACTIVE
ADCBiologicstaleKing Abdullah International Med…Vedotin Plus AVD versus ABV…Phase 2

ABVD (ABVD)

Classical Hodgkin Lymphoma; Hodgkin Lymphoma (Category) · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 96%임상시험 52상태 ACTIVE
ADCBiologicSeagen Inc.Vedotin Plus AVD versus ABV…Phase 2

Adriamycin, vinblastine, and dacarbazine (Adriamycin, vinblastine, and dacarbazine)

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 96%임상시험 50상태 ACTIVE
AntibodystaleGenmabPhase 2

Epcoritamab (Epcoritamab)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#Antibody#Phase2#인기#항체+5
효능 ORR 0%임상시험 50상태 RECRUITING
ADCBiologicPharmacyclics LLC.vedotin plus doxorubicin [A…Phase 3

Procarbazine Hydrochloride (Procarbazine Hydrochloride)

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 · Lugano Classification Limited Stage Hodg

#LuganoClassificationLimitedStage#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 1%임상시험 45상태 RECRUITING
ADCBiologicEisai Inc.Phase 2

DOC Group B (DOC Group B)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 42상태 RECRUITING
ADCBiologicTakedaDM1 in HER2-Positive Breast…Phase 1

TAK228 (TAK228)

Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic; Classical Hodgkin Lymphoma · CD30

#CD30#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 18.4%임상시험 40상태 DISCONTINUED
CGTBiologicstaleBristol Myers Squibbvedotin plus bendamustine a…Phase 1

JCAR017 (JCAR017, JCAR017 (lisocabtagene maraleucel) 2-dose schedule, lisocabtagene maraleucel)

Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#CGT#Phase1#세포유전치료#CAR-T+5
효능 ORR 80.5%임상시험 34상태 ACTIVE
AntibodystaleGrupo Español de Linfomas y Tra…Phase 2

Zevalin (Ibritumomab Tiuxetan, Ibritumomab Tiuxetan (Zevalin))

Non-Hodgkin Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 16%임상시험 30상태 ACTIVE
AntibodystaleADC TherapeuticsPhase 3

Loncastuximab tesirine (Loncastuximab tesirine)

Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 3b Follicular Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#항체#면역항체+4
효능 ORR 94.1%임상시험 30상태 RECRUITING
AntibodystaleJohn ReneauPhase 1

Mogamulizumab (Mogamulizumab)

Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Cutaneous T Cell Lymphoma

#CutaneousTCellLymphoma#Antibody#Phase1#항체#면역항체+5
효능 ORR 25%임상시험 30상태 RECRUITING
CGTBiologicstaleTakedaPhase 1

anti-CD19 CAR-NK (anti-CD19 CAR-NK)

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
효능 ORR 0%임상시험 30상태 RECRUITING
AntibodystaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 60%임상시험 29상태 RECRUITING
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Consolidation with Brentuximab Vedotin)

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 25상태 RECRUITING
ADCBiologicstaleCelgenePhase 2

CC-99282 (CC-99282)

Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 92.9%임상시험 21상태 RECRUITING

2 / 8 페이지

← 이전다음 →